Development of thiolated poly(acrylic acid) microparticles for the nasal administration of exenatide

Drug Development and Industrial Pharmacy

Volumn 40, Issue 12, 2014, Pages 1677-1682

  Millotti, Gioconda ^a   Vetter, Anja ^a   Leithner, Katharina ^a   Sarti, Federica ^a   Shahnaz Bano, Gul ^a   Augustijns, Patrick ^b   Bernkop Schnürch, Andreas ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

Exenatide; Microparticles; Nasal delivery; Thiolated polymers

Indexed keywords

BUFFER; CYSTEINE DERIVATIVE; DRUG CARRIER; EXENDIN 4; POLY(ACRYLIC ACID) CYSTEINE; POLYACRYLIC ACID; THIOL GROUP; UNCLASSIFIED DRUG; ACRYLIC ACID RESIN; CARBOPOL 940; MICROSPHERE; PEPTIDE; THIOL DERIVATIVE; VENOM;

ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CILIARY MOTILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROENCAPSULATION; NONHUMAN; NOSE MUCOSA; PARTICLE SIZE; PRECIPITATION; RESPIRATORY TRACT MUCOSA; TISSUE SECTION; ANIMAL; CELL CULTURE; DRUG EFFECTS; INTRANASAL DRUG ADMINISTRATION; METABOLISM; PIG;

ACRYLIC RESINS; ADMINISTRATION, INTRANASAL; ANIMALS; CELLS, CULTURED; HUMANS; MICROSPHERES; NASAL MUCOSA; PARTICLE SIZE; PEPTIDES; SULFHYDRYL COMPOUNDS; SWINE; VENOMS;

EID: 84922216523     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.842578     Document Type: Article

References (31)

1. Butler AE, Janson J, Bonner-Weir J, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes miellitus. Diabetes 2003;52:102-10.
2. Robles GI, Singh-Franco D. A review of exenatide as adjunctive theraphy in patients with type 2 diabetes. Drug Des Dev Ther 2009; 3:219-40.
3. Mustata G, Dihn SM. Approaches to oral drug delivery for challenging molecules. CRC Crit Rev Ther Drug Carr Sys 2006; 23:1111-35.
4. Khafagy ES, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Delivery Rev 2007;59:1521-46.
5. Ozsoy Y, Gunor S, Cevher E. Nasal delivery of high moleular weight drugs. Molecules 2009;14:3754-90.
6. Leitner VM, Guggi D, Bernkop-Schnurch A. Thiomers in noninvasive polypeptide delivery: in vitro and in vivo characterization of a polycarbophil-cysteine/glutathione gel formulation for human growth hormone. J Pharm Sci 2004;93:1682-91.
7. Illum L. Nasal drug delivery: possibilities, problems and solutions. J Control Rel 2003;87:187-98.
8. Bernkop-Schnürch A, Steininger S. Synthesis ans characterization of mucoadhesive thiolated polymers. Int J Pharm 2000;194:239-47.
9. Clausen A, Bernkop-Schnürch A. In vitro evaluation of the permeation-enhancing effect of thiolated polycarbophil. J Pharm Sci 2000;89:1253-61.
10. Marschütz MK, Bernkop-Schnürch A. Thiolated polymers: selfcrosslinking properties of thiolated 450 kDa poly(acrylic acid) and their influence on mucoadhesion. Eur J Pharm Biopharm 2002;15: 387-94.
11. Bernkop-Schnürch A, Schwarz V, Steininger S. Polymers with thiol groups: a new generation of mucoadhesive polymers? Pharm Res 1999;16:876-81.
12. Leitner VM, Walker GF, Bernkop-Schnurch A. Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins. Eur J Pharm Biopharm 2003;56:207-14.
13. Behl CR, Pimplaskar HK, Sileno AP, Romeo VD. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Delivery Rev 1998;29:89-116.
14. Glorieux S, Van der Broeck W, van der Meulenm SM, et al. In vitro culture of porcine respiratory mucosa explants for studying the interaction of porcine viruses with the respiratotory tract. J Virol Methods 2007;142:105-12.
15. Schmidt MC, Simmen D, Hilbe M, et al. Validation of excised bovine nasal mucosa as in vitro model to study drug transport andmetabolic pathways in nasal epithelium. J Pharm Sci 2000;89: 396-407.
16. Toskala E, Haataja J, Shirasaki H, Rautiainen M. Culture of cells harvested with nasal brushing: a method for evaluating ciliary function. Rhinology 2005;29:17-26.
17. Dimova S. High speed digital imaging method for ciliary beat frequency measurement. J Pharm Pharmacol 2005;57:1-6.
18. Ugwoke MI, Agu RU, Jorissen M. Nasal toxicological investigations of Carbopol-971P formulation of apomorphine: effects on ciliary beat frequency of human nasal primary cell culture and in vivo on rabbit nasal mucosa. Eur J Pharm Biopharm 2000;9:387-96.
19. Merkus P, Romeijn SG, Verhoef JC, et al. Classification of cilioinhibitinf effects of nasal drugs. Laryngoscope 2001;111:595-602.
20. Sanders P, Washington N, Frier M, et al. The deposition of solutionbased and suspension-based aerosols from metered dose inhalers in healthy subjects and asmathic patients. STP Pharm Sci 1997;7: 300-6.
21. Jones N. The nose and paranasal sinuses physiology and anatomy. Adv Drug Delivery Rev 2001;51:5-19.
22. Marttin E, Nicolaas GM, Schipper NGM, Coos Verhoef J. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Delivery Rev 1998;29:13-38.
23. Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today 2002;7:967-75.
24. Deutel B, Greindl M, Thaurer M, Bernkop-Schnürch A. Novel insulin thiomer nanoparticles: in vivo evaluation of an oral drug delievry system. Biomacromolecules 2008;9:278-85.
25. Wadell C, Björk E, Camber O. Nasal drug delivery-evaluation of an in vitro model using porcine nasal mucosa. Eur J Pharm Biopharm 1998;7:197-206.
26. Di Colo G, Zambito Y, Zaino E. Polymeric enhancers of mucosal epithelia permeability: synthesis, transepithelial penetration-enhancing properties, mechanism of action, safety issues. J Pharm Sci 2008;97:1652-80.
27. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 2001;53: 3-22.
28. Sommer JU, Gross S, Hörmann K, Stuck BA. Time-dependent changes in nasal ciliary beat frequency. Eur Arch Otorhinolaryngol 2010;267:1383-7.
29. Jorissen M, Willems T, De Boeck K. Duagnostic evaluation of mucociliary transport: from symptoms to coordinated ciliary activity after ciliogenesis in culture. Am J Rhinol 2000;14:345-52.
30. Hoyer H, Schlocker W, Kafedjiiski K. Preparation and evaluation of microparticles from thiolated polymers via jet milling. Eur J Pharm Biopharm 2008;69:476-85.
31. Dimova S, Mugabowindekwe R, Willems T, et al. Safety-Assestment of 3-methoxyquercetin as an antirhinovial compound for nasal application: effect on ciliary beat frequency. Int J Pharm 2003;263: 95-103.